(Total Views: 724)
Posted On: 06/08/2022 12:36:02 AM
Post# of 154033
Well said.
“this bodes well for leronlimab, as dostarlimab being a mab promotes other mabs. another mab with minimal side effects. a trend. plus a tiny group of 14 patients taken as quality data. cytodyn constantly criticized for too small trial sizes. our ASCO poster should be taken seriously also. enhertu praised for extended survival, as it should. leronlimab is extending survival also. by a lot. with no side effects. love that. “
“this bodes well for leronlimab, as dostarlimab being a mab promotes other mabs. another mab with minimal side effects. a trend. plus a tiny group of 14 patients taken as quality data. cytodyn constantly criticized for too small trial sizes. our ASCO poster should be taken seriously also. enhertu praised for extended survival, as it should. leronlimab is extending survival also. by a lot. with no side effects. love that. “
(4)
(0)
